Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma

Recent clinical trials demonstrated the safety and efficacy of neoadjuvant dabrafenib and trametinib (DT) among patients with surgically resectable clinical stage III BRAFV600E/K mutant melanoma. Although patients achieving a complete pathological response (pCR) exhibited superior recurrence-free su...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2020-11, Vol.31 (11), p.1569-1579
Hauptverfasser: Tetzlaff, M.T., Adhikari, C., Lo, S., Rawson, R.V., Amaria, R.N., Menzies, A.M., Wilmott, J.S., Ferguson, P.M., Ross, M.I., Spillane, A.J., Vu, K.A., Ma, J., Ning, J., Haydu, L.E., Saw, R.P.M., Wargo, J.A., Tawbi, H.A., Gershenwald, J.E., Long, G.V., Davies, M.A., Scolyer, R.A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Recent clinical trials demonstrated the safety and efficacy of neoadjuvant dabrafenib and trametinib (DT) among patients with surgically resectable clinical stage III BRAFV600E/K mutant melanoma. Although patients achieving a complete pathological response (pCR) exhibited superior recurrence-free survival (RFS) versus those who did not, 30% of pCR patients relapsed. We sought to identify whether histopathological features of the pathological response further delineated risk of relapse. Surgical resection specimens from DT-treated patients in two phase 2 clinical trials were reviewed. Histopathological features, including relative amounts of viable tumour, necrosis, melanosis, and fibrosis (hyalinized or immature/proliferative) were assessed for associations with patient outcomes. Fifty-nine patients underwent surgical resection following neoadjuvant DT. Patients achieving pCR (49%) had longer RFS compared with patients who did not (P = 0.005). Patients whose treated tumour showed any hyalinized fibrosis had longer RFS versus those without (P = 0.014), whereas necrosis (P = 0.012) and/or immature/proliferative fibrosis (P = 0.026) correlated with shorter RFS. Multivariable analyses showed absence of pCR or presence of immature fibrosis independently predicted shorter RFS. Among pCR patients, mature/hyalinized-type fibrosis correlated with improved RFS (P = 0.035). The extent and composition of the pathological response following neoadjuvant DT in BRAFV600E/K mutant melanoma correlates with RFS, including pCR patients. These findings support the need for detailed histological analysis of specimens collected after neoadjuvant therapy. •The extent and composition of the pathological response after neoadjuvant DT in BRAFV600E/K melanoma correlates with RFS.•Patients achieving pCR had longer RFS compared with patients who did not.•Hyalinized fibrosis correlated with longer RFS, while necrosis and proliferative fibrosis correlated with shorter RFS.•Absence of pCR or presence of immature fibrosis independently predicted shorter RFS.•Among pCR patients, mature/hyalinized-type fibrosis correlated with improved RFS.
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2020.07.016